Defining Novel Molecular Pathways to Totipotency
Defining Novel Molecular Pathways to Totipotency
批准号:
10102035
负责人:
Jianlong Wang
金额:
$26.41万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-24 至 2023-06-30
中文摘要
项目摘要
全能性,一个显着的细胞可塑性的一个细胞在产生一个完整的有机体与
胚胎和胚外的贡献,是多细胞和发展必不可少的。在小鼠中,完全
全能细胞短暂存在于受精卵和卵裂期卵裂球中,尽管全能2-细胞(2C)-
类细胞(2CLC)也可以在培养的胚胎干细胞(ESCs)中零星产生或遗传诱导产生。
它们是多能性的,只能形成胚胎谱系。最近,扩大潜在的干细胞和
衍生了具有全能性特征的扩展多能干细胞,统称为EPSC,
使用两组不同的小分子抑制剂在体外稳定培养。然而,2CLC和两个EPSC
细胞系在培养条件、转录组和核心多能性因子的表达方面存在差异,提示
替代全能国家。2CLC和EPSC是容易获得的细胞来源,在体外具有价值
理解全能性的模型,这方面的知识对于捕获和稳定
全能2CLC状态,这是目前不可能的。定义这些不同的分子途径
全能细胞将有助于解开全能性的复杂调节机制,
全能2CLC的捕获/稳定。据报道,全能2CLC重新激活转录,
内源性逆转录病毒(ERV),特别是MERVL,其激活现已被发现是致病的
在我们的初步研究中获得全能性。ZSCAN 4在2C期胚胎中也有明显表达,
从ESC状态向2CLC退出的那些零星ESC。通过表征MERVL/ZSCAN 4双
报告基因阳性(DR+/+)ESCs,我们已经开始剖析2CLC的分子途径
全能性和发现miR-344及其直接靶ZMYM 2作为新的正和负调节剂,
分别用于MERVL活化和2CLC全能性。本申请的目的是扩展我们的
了解ESC培养中不同的细胞潜能状态,并定义MERVL对
全能性和探索全能性的转录和转录后机制。我们
假设2CLC代表一种由新分子轴调节的替代全能状态
包括转录和转录后机制。我们建议进行以下研究,
验证我们的假设1)定义EPSC和2CLC中替代全能状态的分子路线图。(二)
确定MERVL元件对2CLC全能性的功能贡献。我们将定义和区分
单个MERVL元件在促进2CLC全能性中的功能作用。3)剖析分子
通过将miR-344建立为理解的新范式,2CLC全能性的潜在机制
哺乳动物全能性了解驱动和诱导全能特征的分子机制,
体外对于理解如何实现最大程度的细胞可塑性至关重要,
维持,从而为有效的重编程和潜在的治疗途径提供更多的选择。
英文摘要
PROJECT SUMMARY
Totipotency, a remarkable cellular plasticity of a single cell in generating a complete organism with both
embryonic and extraembryonic contribution, is essential for multicellularity and development. In mice, fully
totipotent cells exist transiently in the zygote and cleavage-stage blastomeres, although totipotent 2-cell (2C)-
like cells (2CLCs) can also arise sporadically or induced genetically in cultured embryonic stem cell (ESCs)
that are pluripotent and can only contribute to embryonic lineages. Recently, expanded potential stem cells and
extended pluripotent stem cells, collectively known as EPSCs, with totipotency features were derived and
stably cultured in vitro using two distinct sets of small molecule inhibitors. However, 2CLCs and the two EPSC
lines differ in their culture conditions, transcriptomes, and expression of core pluripotency factors, suggestive of
alternative totipotent states. 2CLCs and EPSCs represent easily accessible cell source and valuable in vitro
models for understanding totipotency, the knowledge of which will be critical to capture and stabilize the
totipotent 2CLC state, which is not currently possible. Defining molecular pathways underlying these various
totipotent cells will facilitate unraveling the complex regulatory mechanisms of totipotency and achieving the
capture/stabilization of totipotent 2CLCs. The totipotent 2CLCs were reported to reactivate transcription of
endogenous retroviruses (ERVs), in particular MERVL, whose activation has now been found to be causative
for totipotency in our preliminary studies. ZSCAN4 is also sharply expressed in 2C-stage embryo and marks
those sporadic ESCs exiting from the ESC state towards 2CLCs. By characterizing MERVL/ZSCAN4 double
reporter positive (DR+/+) ESCs, we have begun to dissect the molecular pathways underlying 2CLC
totipotency and discovered miR-344 and its direct target ZMYM2 as novel positive and negative regulators,
respectively, for MERVL activation and 2CLC totipotency. The objective of this application is to extend our
knowledge of the divergent cellular potency states in ESC culture, and define the MERVL contribution to
totipotency and explore transcriptional and post-transcriptional mechanisms underlying totipotency. We
hypothesize that 2CLCs represent an alternative totipotent state that is regulated by a novel molecular axis
encompassing the transcriptional and post-transcriptional mechanisms. We propose the following studies to
test our hypothesis. 1) Define a molecular roadmap for alternative totipotent states in EPSCs and 2CLCs. 2)
Establish the functional contribution of MERVL elements to 2CLC totipotency. We will define and distinguish
functional roles of individual MERVL elements in contributing to 2CLC totipotency. 3) Dissect the molecular
mechanism underlying 2CLC totipotency by establishing miR-344 as a new paradigm for understanding
mammalian totipotency. Understanding the molecular mechanisms that drive and induce totipotent features in
vitro is essential to understanding of how a maximum degree of cellular plasticity can be achieved and
maintained, thereby providing more options for efficient reprogramming and potential therapeutic avenues.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:10071608
-
项目类别:
-
资助金额:$34.06万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:9922386
-
项目类别:
-
资助金额:$41.28万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis
-
批准号:10377330
-
项目类别:
-
资助金额:$41.39万
-
财政年份:2019
-
负责人:Jianlong Wang
-
依托单位:
Defining Molecular Pathways to Expanded Puripotentiality
-
批准号:9792267
-
项目类别:
-
资助金额:$7.54万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
-
批准号:10401429
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells
-
批准号:10176171
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:10428542
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control
-
批准号:9767845
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:10102033
-
项目类别:
-
资助金额:$16.27万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:10219317
-
项目类别:
-
资助金额:$32.94万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Defining Novel Molecular Pathways to Totipotency
-
批准号:9982114
-
项目类别:
-
资助金额:$33.62万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:9756422
-
项目类别:
-
资助金额:$16.88万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281
-
批准号:9903392
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2018
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8305470
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8185973
-
项目类别:
-
资助金额:$31.76万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8515465
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
Oct4 and epigenetic regulation of stem cell pluripotency
-
批准号:8710256
-
项目类别:
-
资助金额:$31.87万
-
财政年份:2011
-
负责人:Jianlong Wang
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Novel-miR-1134调控LHCGR的表达介导拟
穴青蟹卵巢发育的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:崔文晓
-
依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
-
批准号:82304677
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:边兴博
-
依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
-
批准号:82304658
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:刘亚
-
依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
-
批准号:32102747
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李婉雁
-
依托单位:
novel_circ_001042/miR-298-5p/Capn1轴调节线粒体能量代谢在先天性肛门直肠畸形发生中的作用机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:55万元
-
批准年份:2021
-
负责人:唐晓冰
-
依托单位:
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:58万元
-
批准年份:2021
-
负责人:张瑜
-
依托单位:
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
-
批准号:82070530
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:白玉作
-
依托单位:
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
-
批准号:32002421
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:修云吉
-
依托单位:
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
-
批准号:82072775
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:薛皓
-
依托单位:
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
-
批准号:31902347
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2019
-
负责人:闫红伟
-
依托单位: